Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor ago
about
Novel binding motif of ACTH analogues at the melanocortin receptorsMelanocortin receptors, melanotropic peptides and penile erectionDesign, synthesis and biological evaluation of ligands selective for the melanocortin-3 receptorInteractions of human melanocortin 4 receptor with nonpeptide and peptide agonistsStructure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 receptorNovel α-MSH analog causes weight loss in obese rats and minipigs and improves insulin sensitivityMelanocortin receptors in rat liver cells: change of gene expression and intracellular localization during acute-phase responseThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsSolution structures of cyclic melanocortin agonists and antagonists by NMR.Unraveling the genetics of human obesity.Engineering the melanocortin-4 receptor to control constitutive and ligand-mediated G(S) signaling in vivo.A small molecule agonist THIQ as a novel pharmacoperone for intracellularly retained melanocortin-4 receptor mutants.Solid-phase peptide head-to-side chain cyclodimerization: discovery of C(2)-symmetric cyclic lactam hybrid α-melanocyte-stimulating hormone (MSH)/agouti-signaling protein (ASIP) analogues with potent activities at the human melanocortin receptorsFunctional evaluation of THIQ, a melanocortin 4 receptor agonist, in models of food intake and inflammation.Design, synthesis, and biological evaluation of new cyclic melanotropin peptide analogues selective for the human melanocortin-4 receptorRecent developments in our understanding of melanocortin system in the regulation of food intake.Control of penile erection by the melanocortinergic system: experimental evidences and therapeutic perspectives.Classification of scaffold-hopping approachesThe melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.Temporal cAMP Signaling Selectivity by Natural and Synthetic MC4R Agonists.Opioid and melanocortin receptors: do they have overlapping pharmacophores?Chiral Effect of a Phe Residue in Position 3 of the Dmt(1)-L(or D)-Tic(2) Analogues on Opioid Functional Activities.MC4R dimerization in the paraventricular nucleus and GHSR/MC3R heterodimerization in the arcuate nucleus: is there relevance for body weight regulation?Key amino acid residues in the melanocortin-4 receptor for nonpeptide THIQ specific binding and signaling.Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.Utilize conjugated melanotropins for the earlier diagnosis and treatment of melanomaPharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.Structure-activity relationships of melanocortin agonists containing the benzimidazole scaffold.Antibodies against the melanocortin-4 receptor act as inverse agonists in vitro and in vivo.Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors.Modified melanocortin tetrapeptide Ac-His-dPhe-Arg-Trp-NH at the arginine side chain with ureas and thioureas.Synthesis and Structure-Activity Relationships of Substituted Urea Derivatives on Mouse Melanocortin Receptors.Melanocortin-4 Receptor Activation Stimulates Hypothalamic Brain-Derived Neurotrophic Factor Release to Regulate Food Intake, Body Temperature and Cardiovascular Function
P2860
Q24315086-26B8542D-B366-4171-8D5A-26BBBE46A4BCQ24647691-87FE9328-4FF1-43C5-B5ED-5AFE7E912628Q24649952-8B97369A-FAAD-4F9C-9A52-183846AABEA6Q24653618-1238D898-6B4A-4D9C-A722-6D38E6FB205FQ24653947-DC282B06-1D8A-418A-81F2-6F85E6A072D9Q28301492-C75D9252-5156-4AA9-8F34-33633CE3FF49Q28573568-D2B09C33-C3D2-4E85-9E3C-4C6E583FE6C7Q30486707-B772A49C-4BF3-4A3B-A534-9075775BCA87Q30909300-D39614F5-50D5-4A18-8BE7-23E7B49D5A9EQ33267907-F3095EAE-B9A8-408A-ACC1-4C22A4EA83C6Q33292675-7990DEF4-434D-44E1-9860-E9F4B1BF77B9Q33970155-7F16C221-E953-4980-A658-53478DF071EBQ34583185-CBBBD71E-8184-495C-A6EC-6B65213CD8C3Q34715986-155C31FA-66B1-4719-91ED-2ABDFEF67CCFQ35574655-F60CDB2A-539C-4D61-A9C8-5F909BCC652AQ35597667-DEB7D17C-787B-4E16-A551-29C03DB56C78Q35855077-9D769FDD-FA7F-42FE-815B-DD746AF896FCQ35893996-59AFD11F-5AEB-4B5D-BE4F-207271093D63Q36003378-5A32080E-7138-4872-A06D-E21CA99321BFQ36232983-F8488B8B-46C7-430E-89F3-76954A50E411Q37218872-9F6F34D2-FDF3-4FCB-B259-EBAAEE011816Q37640669-7C1CB377-3B9F-4A66-BF23-E95E80BDE0BCQ37983474-65FC2984-CD56-43BB-B4D2-08C1584D1EAFQ39123206-D5A7752A-A162-4294-B0F5-B02DBEDB5713Q39211934-A110B6D4-ECB5-4711-A7A6-3E602F379AAFQ39593902-34F2473C-EB48-4D15-9185-3DA1B9D50A63Q39704718-2EF7C102-E994-4D51-91E9-87F02E6D1EB1Q40125880-B422A990-897D-49C8-8CC1-158834CEF10CQ40166731-383AB53A-7CCB-4A29-BA7A-FD45FB9BE17EQ40239862-793C3B14-6E82-441D-89D0-6023D1863964Q40363165-733D1CA3-60DD-4DE4-996A-07FB4306C01DQ47120733-FCD067AA-DBC5-41FB-8A42-57042720B6FDQ58047139-E0DBDE23-8FDC-44F4-8800-478EE19BEC88
P2860
Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor ago
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Design and pharmacology of N-[ ...... ocortin subtype-4 receptor ago
@en
Design and pharmacology of N-[ ...... ocortin subtype-4 receptor ago
@nl
type
label
Design and pharmacology of N-[ ...... ocortin subtype-4 receptor ago
@en
Design and pharmacology of N-[ ...... ocortin subtype-4 receptor ago
@nl
prefLabel
Design and pharmacology of N-[ ...... ocortin subtype-4 receptor ago
@en
Design and pharmacology of N-[ ...... ocortin subtype-4 receptor ago
@nl
P2093
P356
P1476
Design and pharmacology of N-[ ...... ocortin subtype-4 receptor ago
@en
P2093
Alison M Strack
Andrew D Howard
Arthur A Patchett
Brenda Palucki
Constantin Tamvakopoulos
D Euan MacIntyre
David B R Johnston
David H Weinberg
Doreen E Cashen
Erin McGowan
P304
P356
10.1021/JM025539H
P407
P577
2002-10-01T00:00:00Z